97 related articles for article (PubMed ID: 11832029)
1. [Expression of Fas ligand in urogenital malignant cell lines and renal cell carcinoma].
Li H; Yu L; Guo Y; Ding Y; Liu L
Zhonghua Wai Ke Za Zhi; 2000 Mar; 38(3):201-3. PubMed ID: 11832029
[TBL] [Abstract][Full Text] [Related]
2. Fas labeling status does not correlate with apoptosis of renal cell carcinoma in vivo.
Koga F; Arai K; Kamai T; Abe H; Yoshida K
Anticancer Res; 2001; 21(5):3193-7. PubMed ID: 11848472
[TBL] [Abstract][Full Text] [Related]
3. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
4. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis.
Elsamman EM; Fukumori T; Tanimoto S; Nakanishi R; Takahashi M; Toida K; Kanayama HO
BJU Int; 2006 Sep; 98(3):668-73. PubMed ID: 16925770
[TBL] [Abstract][Full Text] [Related]
5. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
Sejima T; Miyagawa I
Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
[TBL] [Abstract][Full Text] [Related]
6. Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.
Prado-Garcia H; Aguilar-Cazares D; Meneses-Flores M; Morales-Fuentes J; Lopez-Gonzalez JS
Cancer Immunol Immunother; 2008 Mar; 57(3):325-36. PubMed ID: 17668204
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
8. Detection of Fas/APO-1 in six human urogenital malignant cell lines with flow cytometry.
Li H; Yu L; Guo Y; Ding Y; Liu L
Chin Med J (Engl); 1998 May; 111(5):408-11. PubMed ID: 10374348
[TBL] [Abstract][Full Text] [Related]
9. [Expression of Fas in six human urogenital malignant cell lines].
Li HJ; Yu LZ; Guo YL; Ding Y
Ai Zheng; 2002 May; 21(5):456-9. PubMed ID: 12452031
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of GRP78 in renal cell carcinoma and its significance.
Fu W; Wu X; Li J; Mo Z; Yang Z; Huang W; Ding Q
Urology; 2010 Mar; 75(3):603-7. PubMed ID: 19616278
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis.
Mikami S; Oya M; Mizuno R; Murai M; Mukai M; Okada Y
Cancer Sci; 2006 Sep; 97(9):875-82. PubMed ID: 16856880
[TBL] [Abstract][Full Text] [Related]
13. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
14. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
15. The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma.
Ogawa S; Nagao M; Kanehiro H; Hisanaga M; Ko S; Ikeda N; Nakajima Y
Anticancer Res; 2004; 24(3a):1569-79. PubMed ID: 15274324
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Itoh N; Tsukamoto T
Int J Urol; 2006 Mar; 13(3):265-70. PubMed ID: 16643621
[TBL] [Abstract][Full Text] [Related]
17. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
Cheung C; Vesey D; Cotterill A; Douglas M; Gobe G; Nicol D; Johnson D
Int J Urol; 2005 Jan; 12(1):17-28. PubMed ID: 15661050
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence.
Belluco C; Esposito G; Bertorelle R; Alaggio R; Giacomelli L; Bianchi LC; Nitti D; Lise M
Eur J Surg Oncol; 2002 Mar; 28(2):120-5. PubMed ID: 11884046
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
20. Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation.
Wethkamp N; Ramp U; Geddert H; Schulz WA; Florl AR; Suschek CV; Hassan M; Gabbert HE; Mahotka C
Eur J Cancer; 2006 Jan; 42(2):264-74. PubMed ID: 16386893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
